ABSTRACT
Infection by high-risk human papillomavirus (hrHPV) causes over 95% of all cervical cancers (CCs) and its precursor lesions, high-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia grades 2 to 3 (HSIL/CIN2-3). 1 Although most hrHPV infections are transient productive lesions that spontaneously regress, in about 10% of the cases, the human papillomavirus (HPV) infection cannot be cleared. 2, 3 This persistence of the virus is a necessary condition for the development of HSIL/ CIN2-3 (transforming lesions) and CC (HSIL/CIN2+).
Different factors have been associated with hrHPV persistence and, therefore, with the development of HSIL/ CIN2+. Women with hrHPV persistence or abnormal cytologic result are considered a group at risk for HSIL/ CIN2+. Thus, according to the current guidelines, 4-7 these women warrant immediate colposcopy. However, even when HSIL/CIN2+ is adequately ruled out, women with persistent hrHPV infection are still at substantial risk of HSIL/CIN2+ development over time compared with those testing negative for hrHPV. 8, 9 There is no specific follow-up for hrHPV-positive women with no underlying HSIL/CIN2+, and stratifying the risk of HSIL/CIN2+ in these women is particularly challenging.
One of the strategies proposed to stratify the risk of underlying HSIL/CIN2+ in women with hrHPV infection is HPV genotyping. Indeed, the risk of developing premalignant lesions and CC differs according to the hrHPV type. HPV 16 is the most prevalent genotype and is associated with the highest risk of CC. 10 HPV 18 is the second most frequent genotype and is especially associated with adenocarcinoma. 11 In contrast, the risk of other hrHPV genotypes seems to be lower. 12 Another biomarker that has been related to the risk of HSIL/CIN2+ is the combined detection of p16, a cell cycle regulatory protein that induces cell cycle arrest under physiologic conditions, and Ki-67, a proliferation marker within the same cervical epithelial cell. 13 HPV 16/18 genotyping and p16/Ki-67 dual-staining cytology have mainly been evaluated as markers of risk of underlying HSIL/CIN2+. However, the value of these two biomarkers in the management of women with hrHPV infection in whom an underlying HSIL/CIN2+ has been adequately ruled out has not been evaluated. The aim of this study was to evaluate the prognostic value of these two biomarkers in women with a positive hrHPV test but with negative cytology results and in whom HSIL/CIN2+ was excluded at the baseline evaluation in the colposcopy clinic.
Materials and Methods

Study Population and Case Selection
This prospective study was conducted at the referral Colposcopy Unit of the Hospital Clinic of Barcelona. From October 2009 to September 2015, women referred to the Colposcopy Unit due to an abnormal cervical cytology result within the previous 6 months were included in the study. In the first visit, a cervical sample for hrHPV testing, cytology, HPV genotyping, and p16/Ki-67 dual staining was obtained from all the women. They also underwent a digital colposcopy as well as at least one biopsy.
All women fulfilling the following criteria at the baseline visit at the colposcopy clinic were included in the study: (1) a positive hrHPV test, (2) negative cytology, (3) histologic diagnosis different from HSIL/CIN2+, (4) no previous HPV vaccination, and (5) no HIV infection or other cause of immunosuppression. Samples without sufficient material for hrHPV genotyping and dual staining were excluded from the study. Women with abnormal cytology at the baseline visit at the colposcopy clinic were excluded from the study even if colposcopy and the biopsy specimen did not show HSIL/CIN2+ to minimize a possible bias of underdiagnosed HSIL/CIN2+. Thus, we selected only women with negative cytology in whom underlying HSIL/CIN2+ had been carefully ruled out.
The Institutional Ethical Review Board of the Hospital Clinic approved the study (HCB/2016/0672). All women provided written consent for the use of biological specimens for research purposes.
Colposcopy Evaluation
A digital colposcopy was performed by experienced colposcopists using an Olympus EvisExera II CV-180 colposcope (Olympus, Tokyo, Japan). First, the colposcopist applied 5% acetic acid. To detect "fast fader" lesions, the acetic acid was repeatedly reapplied to the cervix using cotton balls for 1 to 2 minutes. We described colposcopy findings following the criteria of the International Federation for Cervical Pathology and Colposcopy (Río de Janeiro 2011). 14, 15 Original squamous epithelium, columnar epithelium, and the transformation zone were considered normal colposcopy findings. Smooth surface with an irregular outer border; slight acetowhite staining that was slow to appear and quick to disappear; mild, speckled partial iodine positivity; and fine punctuation or fine regular mosaic were considered grade 1 changes suggestive of low-grade intraepithelial squamous lesion/cervical intraepithelial neoplasia grade 1 (LSIL/CIN1). Smooth surface with a sharp outer border, dense acetowhite staining appearing early and being slow to resolve, iodine negativity in a previously densely white epithelium, coarse punctuation or wide irregular mosaic, and dense acetowhite staining of the columnar epithelium were considered grade 2 changes suggestive of HSIL/CIN2-3. We recorded the size of the lesion according to the quadrants of the cervix involved.
During the colposcopy evaluation, at least one biopsy specimen was obtained. Up to four biopsy speciens were collected from different abnormal areas or from different regions in one large complex abnormal area of the cervix. If fewer than four colposcopy-directed biopsy specimens were taken, a random biopsy (nontargeted biopsy) specimen from apparently normal epithelium from the transformation zone was also taken. 16 Endocervical curettage using a Kevorkian curette was performed in all women with a noncompletely visible transformation zone.
Liquid-Based Cytology
Acytobrush was used to collect cervical samples, which were stored in PreservCyt solution (Hologic, Marlborough, MA) for ThinPrep liquid-based cytology and hrHPV testing. We used the ThinPrep T2000 slide processor (Hologic) to prepare thin-layer cytology slides that were stained using the Papanicolaou (Pap) method. A cytotechnologist evaluated the cytology slides, and then a pathologist (A. Saco and J.O.) confirmed the result using the revised Bethesda nomenclature. 17 Subsequently, samples were centrifuged. The pellets were stored at -80°C until further processing.
DNA Isolation, hrHPV Detection, and Genotyping
DNA isolation from the cervical samples kept in PreservCyt was performed using the QIampMinelute Virus Spin kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. 18 In brief, 10 μL of the isolated DNA was amplified by GP5+/6+ polymerase chain reaction (PCR), and 5 μL of GP5+/6+ amplifiers was used for hrHPV detection by the enzyme immunoassay (Diassay, Rijswijk, the Netherlands). The cutoff value to classify samples as positive for hrHPV was threefold the mean optical density (OD) of the PCR-negative controls (OD ≤0.120).
Individual hrHPV genotypes of enzyme immunoassay-positive samples were identified using the commercially available LMNX Genotyping kit HPV GP HR (Labo Bio-medical Products B.V., Rijswijk, the Netherlands) according to the manufacturer's instructions. 18, 19 Briefly, the biotinylated PCR products were hybridized to HPV type-specific probes attached to color-coded beads, targeting 18 
p16/Ki-67 Dual Staining
Immunohistochemical p16/Ki-67 dual staining was performed with the automated immunohistochemistry Tech-Mate 500 (Dako, Carpinteria, CA) using the CINtec Plus kit (Roche-mtm Laboratories, Heidelberg, Germany) according to the manufacturer's instructions. 20, 21 The slides were run in batches of 24 and subsequently evaluated by a trained cytotechnologist. To confirm the presence of the minimum criteria for squamous cellularity as defined by the Bethesda 2001 terminology, an initial evaluation was performed. 17 Subsequently, the slides were interpreted as positive by dual staining analysis, independently of the morphologic interpretation, when the presence of double immunoreactive cervical epithelial cells (ie, cells with simultaneous brown cytoplasmic p16 and red nuclear Ki-67 immunostaining) was detected. All slides with dual staining-positive cell(s) were reviewed by a pathologist (J.O.) to confirm the result. The observers evaluating the p16/Ki-67 dual staining were blinded to the results of the Pap-stained cytology and the hrHPV testing.
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Histologic Diagnosis
All the histologic samples were fixed in 10% neutral buffered formalin and embedded in paraffin following routine procedures. We used H&E to stain formalin-fixed, paraffin-embedded 4-µm sections. Our pathologist (J.O.) reviewed all the histologic samples to confirm or exclude the presence or absence of a squamous intraepithelial lesion/CIN and its grade. Pure morphologic criteria based on the H&E-stained sections were used to establish the histologic diagnoses and always with no prior knowledge of HPV status or the cytology result. Biopsy specimens were classified as normal, LSIL/CIN1, and HSIL/CIN2+ according to the lower anogenital squamous terminology criteria.
1 p16 immunohistochemical staining was performed in all the cervical samples obtained. A positive block staining for p16 in the dysplastic area was required for the diagnosis of HSIL/CIN2+.
Follow-up Protocol
Follow-up visits consisted of cytology, hrHPV testing, and colposcopy and were scheduled every 6 months. In case of an abnormal cytologic result detected during follow-up, new colposcopy-directed biopsies, random biopsies of the transformation zone, or endocervical curettage were performed. Colposcopy-directed biopsies were also repeated when worsening of the colposcopic pattern was identified during follow-up.
Women with a confirmed histologic diagnosis of HSIL/CIN2+ underwent excisional treatment by loop excision of the transformation zone and left the study. In cases in which all the tests became negative during follow-up, the women returned to routine screening.
Final Outcome and Diagnostic Criteria
Progression was defined as HSIL/CIN2+ or adenocarcinoma in situ histologically diagnosed at any time during follow-up. Persistence was defined as a positive hrHPV testing result, persistent cytologic abnormalities, and/or histologic diagnosis of LSIL/CIN1 at the end of follow-up. Regression was defined as a negative hrHPV testing result, a negative Pap test result, and, if available, a negative histologic diagnosis at the end of follow-up.
Statistical Analysis
Data analysis was performed using SPSS version 20.0 software (SPSS, Chicago, IL). Categorical variables are presented as absolute number and percentages and compared using the χ 2 or Fisher exact test. Continuous variables are presented as mean and SD and were compared using the analysis of variance test. Kaplan-Meier curves and Cox models were used to analyze the risk estimation of progression to HSIL/CIN2+ and regression of hrHPV infection at the end of follow-up. P values less than .05 were considered statistically significant.
Results
In total, 218 women fulfilled the inclusion criteria. Eighteen women were excluded because of the lack of sufficient material for biomarker assessment. Thus, 200 women were included in the study. The mean (SD) age of the overall group was 38.4 (11.9) years. The median follow-up period was 23.9 months (range, 6.1-65.8 months). Progression to HSIL/CIN2+ was observed during follow-up in 16 (8%) women. The median time from the baseline visit to progression was 18.5 months (range, 6.1-65.6 months). In 76 (38%) women, the hrHPV infection or the cytologic abnormality persisted at the end of the follow-up period, and in 108 (54%) women, infection regressed during follow-up.
The clinical characteristics (age, smoking habits, result of the referral Pap test, abnormal colposcopy findings at the first visit) as well as the results of the biomarkers analyzed (HPV genotyping and p16/Ki-67 dual staining) upon entry in the study according to the main outcomes are shown in ❚Table 1❚. Women showing progression and persistence were older than those showing regression. The colposcopy pattern at the first visit was not associated with the risk of progression. HPV 16/18 was identified in 55 women, and hrHPV types other than 16/18 were identified in 145 women. Women testing positive for HPV 16/18 were at higher risk of progression and persistence than those positive for other hrHPV types (20% and 40% vs 7.9% and 28.6%, respectively; P = .003). A positive result for p16/ Ki-67 dual staining was identified in 25 women. No association was observed between progression, persistence or regression, and the result of the p16/Ki-67 dual staining.
❚Figure 1❚ shows the cumulative incidence of progression to HSIL/CIN2+ in women with infections by HPV 16/18 and by other hrHPV types. The cumulative risk of progression was higher in women with HPV 16/18. Similarly, the risk of regression of hrHPV infection was significantly lower in women with HPV 16/18 infection ❚Figure 2❚.
The 95% CI, 1.3-10.4) were associated with the risk of progression. In the multivariate analysis, only HPV 16/18 was identified as an independent risk factor of progression to HSIL/CIN2+ (HR, 3.0; 95% CI, 1.0-9.1).
❚Table 3❚ shows the clinical characteristics of the 16 women who progressed to HSIL/CIN2+ during follow-up. Six (37.5%) of these women showed an abnormal colposcopy pattern at the first evaluation. At progression to HSIL/CIN2+, the colposcopy was abnormal in seven (43.8%) of 16 women. In 15 of 16 women who progressed to HSIL/CIN2+, the biopsy performed during follow-up showed abnormal cytology. In these women, there was a change in the colposcopic evaluation compared with the first visit. In one woman, the biopsy was performed at follow-up because of grade 1 changes in a previously normal colposcopic pattern. In the nine women with a normal colposcopic pattern at progression, the lesion was detected by a random biopsy of the transformation zone.
Of the 108 women showing regression during the follow-up, all 66 who had a normal colposcopy pattern at the first visit showed a normal colposcopy at the end of follow-up. Of the 40 (85%) women showing grade 1 changes at the first colposcopy, 34 presented a normal colposcopy at the end of the follow-up, whereas in six (15%), the grade 1 changes persisted. Of the two women with regression and grade 2 changes at the initial colposcopy, one had a normal colposcopy at the end of follow-up and the other showed grade 1 changes.
Discussion
The present study shows that HPV 16/18 genotyping can identify the subset of women at high risk of progression to HSIL/CIN2+ and long-term persistence of hrHPV infection in hrHPV-positive women referred to colposcopy with no evidence of HSIL/CIN2+ and a negative cytology result at the initial visit. In contrast, dual-staining cytology was found to add very little or no information. To our knowledge, this is the first study to evaluate and compare the predictive value of these two biomarkers in women with hrHPV infection in whom a HSIL/CIN2+ has been adequately ruled out and with no cytologic abnormalities at the baseline visit.
The risk of developing transforming lesions varies for the different hrHPV types. HPV 16 and HPV 18 have a high capacity of persistence. 10, 11 Thus, their detection has been shown to be a risk factor of either underlying or progression to HSIL/CIN2+. The study with the longest follow-up (10 years) published to date showed a cumulative risk of progression to HSIL/CIN2 of 20.7% for women with HPV 16, 17.7% for women with HPV 18 infection, and only 3% for women with other hrHPV genotypes. 23 It has also been estimated that in women who are positive for HPV 16/18, even with normal cytology, the risk of progression to HSIL/CIN2+ at 3 years is about 19.8%, being higher than the 7.9% observed in women with infections by other hrHPV genotypes. 5, 24 These figures are in keeping with the results observed in the present series, showing that women with HPV 16/18 infection have a cumulative risk of 16% for developing HSIL/CIN2+ at 2 years of follow-up. Moreover, in the present study, women with HPV 16/18 infections had a lower probability of regression compared with those with other hrHPV infections (36.3% vs 60.7%). These results have also been observed in previous studies 23, 25 and suggest that progression to HSIL/CIN2+ likely increases over time.
Several studies have reported that p16/Ki-67 dual staining may improve the detection of HSIL/CIN2+ when it is performed as a secondary tool in the triage of hrH-PV-positive women. 22, 26 p16/Ki-67 dual staining has also been evaluated in women with mild abnormalities in the Pap cytology, with promising results in terms of diagnosis of HSIL/CIN2+. 20, 21, 27, 28 In women with hrHPV infection and a negative cytology result, some studies have shown that p16/Ki-67 dual staining is an adequate predictor of progression, with a 5-year cumulative incidence risk of HSIL/CIN2+ of 23%, which is higher than the 5% risk reported in women showing negative dual-staining cytology. 29, 30 All these studies included women participating in population-based cervical screening with a negative cytology and a positive HPV test. In contrast, in our study, p16/Ki-67 dual staining did not provide any information about the risk of progression or persistence. Remarkably, all the women included in our series had not only a negative cytology but also a complete colposcopic examination, which excluded an underlying HSIL/CIN2±. The different characteristics of the women included in these studies might justify the discordance. On the other hand, other studies showing a higher risk of progression for women with a positive p16/Ki-67 test found a correlation between HPV 16 infection and positive p16/Ki-67 staining, suggesting that the prognostic value of this biomarker may have been overestimated. In our study, the colposcopy pattern at the first visit was not associated with the risk of progression. These results are in keeping with previously published studies. 3 Only seven of the 16 women who progressed to HSIL/ CIN2+ during follow-up presented an abnormal colposcopy at the time of HSIL/CIN2+ diagnosis. In six of these women, the altered pattern was already present at the first visit (five women with grade 1 changes and one with grade 2 changes), although the histologic study was normal or showed LSIL/CIN1. Only one additional woman developed an abnormal colposcopy pattern (grade 1 changes) during follow-up. Therefore, nine cases of HSIL/CIN2+ were not evident at the colposcopy examination. Previous studies have suggested that nontargeted biopsy (random biopsies) of the transformation zone may detect colposcopically nonvisible HSIL/CIN2+ and should be considered in women with HPV 16/18 infection due to their higher risk of developing HSIL/CIN2+. 16, 32 Recently, the American Society for Colposcopy and Cervical Pathology published the Colposcopy Standards recommendations addressing the role of colposcopy and the performance of biopsy sampling for CC prevention. Despite its possible limitations, colposcopy is considered the gold standard to guide biopsy sampling in these women. 16, 33 However, the new colposcopy guidelines suggest that random biopsies of the transformation zone should be recommended to women at very high risk of HSIL/CIN2+ (high-grade cytology, HPV 16/18 infection, abnormal colposcopy appearance). 34 The high proportion (31.2%) of HSIL referral cytology among the women who progressed to HSIL/CIN2+ suggests the presence of occult and colposcopically nonvisible HSIL/CIN2-3. However, the probability of missing an underlying HSIL/CIN2+ was extremely low in these women since very accurate colposcopic and biopsy evaluation was performed, including colposcopy-directed biopsy of all abnormal areas, a random biopsy of the transformation zone when fewer than four biopsy specimens had been obtained, and endocervical curettage when the transformation zone was not completely visible. Moreover, in the four women referred for HSIL cytology who progressed to HSIL/CIN2±, the time from the baseline visit to progression (range, 11.1-21.6 months) suggests that progression to HSIL/CIN2+ is more likely than the presence of an underlying high-grade lesion. These findings suggest that close follow-up should be recommended in women with an HSIL cytology result and that random biopsies of the transformation zone or endocervical curettage should be performed in these women, even in the absence of an altered colposcopy pattern, to rule out occult HSIL/CIN2+. 16, 33 The main strength of this study is that all women were prospectively recruited and followed over a long period (2 years). Moreover, a well-defined follow-up routine was established, which included liquid-based cytology, hrHPV testing, and colposcopy every 6 months with directed and/or random biopsies of the transformation zone and endocervical curettage in the case of an HSIL result in the Pap test or significant worsening in the colposcopy study. This close follow-up allowed early diagnosis of HSIL/CIN2+ development. Another strength of this study is that cytologic evaluations, hrHPV testing, HPV genotyping, and p16/Ki-67 dual staining were performed in the same laboratory by the same experienced team of pathologists and cytotechnicians. This is especially relevant regarding the cytology evaluation because of its known interobserver variability, inherent to all morphologic techniques. 35 The main limitation of this study is the relatively small number of women included, which may have resulted in a very small number of women who progressed to HSIL/CIN2+. However, the percentage of women showing progression is in keeping with that observed in previous reports. 16, 34, 36 To be as accurate as possible excluding possible underlying HSIL/CIN2+, only women showing a negative cytology result at the first visit were finally included, and all women with cytologic mild abnormalities at the initial visit were excluded. It has been shown that HSIL/CIN2+ may be found in up to 16% of women with hrHPV infection and cytologically mild abnormalities. 7 An abnormal colposcopy pattern was not considered an exclusion criterion because an accurate histologic evaluation of all abnormal patterns, random biopsies from areas not suggestive of HSIL/CIN2+, and endocervical evaluation in all cases in which the transformation zone could not be properly assessed was performed.
Conclusions
HPV 16/18 genotyping in women with a positive hrHPV test with no lesion or minor abnormalities at referral colposcopy is able to identify a subset of women with an increased risk of progression to HSIL/CIN2+ and persistence of the hrHPV infection, while dual-staining cytology seems to add very little information. These results suggest that close follow-up of women with HPV 16/18 infection would allow earlier diagnosis of premalignant lesions. Random biopsies of the transformation zone or endocervical curettage should be considered in the study of women with HPV 16/18 infection due to the high risk of HSIL/CIN2+ development not always visible in the colposcopic evaluation.
